JP Morgan attendees share their views, and biotech is king.
|
JPMorgan's annual healthcare confab. highlights trends and themes shaping the sector.
|
Healthcare, IT sectors lead charge, along with renewables.
|
As the life sciences industry matures, VCs need to go with the flow.
|
The battle builds over research data.
|
Red Herring magazine’s bioscience news briefs for the week of May 29, 2006.
|
Redmond and Hyderabad firms to develop software system.
|
Was the acquisition worth the trouble?
|
Are VCs betting the farm on one horse?
|
The technology is generating renewed interest in the VC and medical communities.
|
Growth is shifting, but the industry is none the poorer for that.
|
Bioscience news briefs for the week of April 10, 2006.
|
The Indian pharmaceutical giant buys Romanian and Belgian generic drug companies.
|
Startup Nereus gets $18.3 million to look for new drugs in marine microbes.
|
The race is on to serve world’s largest diabetics population.
|
A study claims Celebrex should not receive preferential treatment over Vioxx.
|
Whether Wyeth’s bid to become more ‘biotech’ works or not, startups will benefit.
|
The country’s pharmaceutical firms grow up and out while multinationals move in, but the giants don’t always get what they want.
|
As standard generic drugs grab more business from big pharmas, biogenerics are held up by regulators.
|
Biopharma and medical devices scored in 2005. Buyers want to get in early.
|
Page
1
of
2
|